OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from โ1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SINT
Sintx Technologies, Inc.
There isn't enough reported data to score SINT yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SINT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
SINT's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | โ |
| Current | 13x | $31.94 | โ |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SINT PE Valuation
SINT has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SINT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SINT's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SINT on earnings quality, reporting a profit while its opponent remains loss making.
SINT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.19 | +$7.98 |
| Q2 2026 | -$5.41 | +$8.26 |
| Q1 2026 | -$5.57 | +$10.80 |
| Q4 2025 | -$6.16 | +$30.92 |
| Q3 2025 | -$10.17 | +$153.79 |
| Q2 2025 | -$13.67 | +$305.33 |
| Q1 2025 | -$16.37 | +$455.02 |
SINT lost $2.19 per share over the past year, a smaller loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SINT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SINT on profitability, with a higher operating margin.
SINT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2M | +953% |
| Q2 2026 | $452K | +199% |
| Q1 2026 | $380K | +3% |
| Q4 2025 | $290K | -46% |
| Q3 2025 | $208K | -74% |
| Q2 2025 | $151K | -82% |
| Q1 2025 | $369K | -46% |
| Q4 2024 | $542K | -40% |
SINT's revenue is growing: $2M last quarter, up 953% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -75% | +1538 points |
| Q2 2026 | -639% | +1126 points |
| Q1 2026 | -844% | -198 points |
| Q4 2025 | -799% | -480 points |
| Q3 2025 | -1613% | -811 points |
| Q2 2025 | -1765% | -1449 points |
| Q1 2025 | -646% | -180 points |
| Q4 2024 | -320% | -18 points |
SINT's operating margin was โ75% last quarter, up 1538 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SINT on cash generation, producing positive trailing cash flow while its opponent burns cash.
SINT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.5M | +$1.1M |
| Q2 2026 | -$2.9M | -$442K |
| Q1 2026 | -$2.5M | -$1.1M |
| Q4 2025 | -$2.4M | -$1.1M |
| Q3 2025 | -$2.6M | -$20K |
| Q2 2025 | -$2.4M | +$165K |
| Q1 2025 | -$1.4M | +$1.5M |
| Q4 2024 | -$1.3M | +$1.9M |
SINT has burned cash in almost every quarter: โ$9M over the past year, against โ$8M the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SINT Net Leverage
SINT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SINT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 17.8 | Oversold |
SINT's weekly RSI is 40 (neutral) and its Stochastic is 18 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SINT PE vs Healthcare Sector
SINT has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SINT on trend strength, trading above more of its moving averages.
SINT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.79 | 14% below |
| 20 week MA | $1.71 | 9.9% below |
| 50 week MA | $2.39 | 36% below |
| 100 week MA | $2.86 | 46% below |
| 200 week MA | $92.7 | 98% below |
SINT is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SINT on returns for 2026, with the stronger performance.
SINT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29,200.0 | $34,400.0 | +18% |
| 2021 | $34,400.0 | $14,000.0 | -59% |
| 2022 | $14,000.0 | $1,640.0 | -88% |
| 2023 | $1,640.0 | $76.3 | -95% |
| 2024 | $76.3 | $3.78 | -95% |
| 2025 | $3.78 | $3.74 | -1.1% |
| 2026 YTD | $3.74 | $1.54 | -59% |
SINT has finished five years in a row lower, and it's down 59% so far in 2026.